DCC-2812 for Advanced Genitourinary Cancers
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test the safety and early effectiveness of a new drug, DCC-2812, for treating advanced kidney, bladder, or prostate cancers. It focuses on patients whose cancer has spread and who haven't recently received other cancer treatments. Participants should have one of these cancers and be able to take medicine orally. The trial will explore how the drug works at different doses to determine the safest and most effective amount.
As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding how it works in people.
Do I need to stop my current medications for the trial?
The trial requires that you have not received any prior anticancer or investigational therapy within a certain timeframe before starting the study drug. It doesn't specify about other medications, so it's best to discuss your current medications with the trial team.
Is there any evidence suggesting that DCC-2812 is likely to be safe for humans?
Research has shown that DCC-2812 is a new treatment being tested for certain advanced cancers, including kidney, bladder, and prostate cancers. In studies so far, patients have received increasing doses of DCC-2812 to determine a safe dosage. This process helps researchers understand how the drug interacts with the body and its effects on cancer.
Since DCC-2812 remains in early testing, detailed reports on tolerance and potential side effects are limited. However, this trial phase primarily focuses on safety assessment. As the drug is quite new, researchers closely monitor for any issues.
When a drug is at this stage, it indicates that more information about its safety is needed. Participants in these trials contribute to gathering this crucial information.12345Why do researchers think this study treatment might be promising?
Unlike the standard treatments for advanced genitourinary cancers, which often include chemotherapy, immunotherapy, or targeted therapy, DCC-2812 works differently by focusing on a novel mechanism of action. Researchers are particularly excited about DCC-2812 because it targets specific pathways involved in cancer cell growth and survival, potentially offering a more precise approach to treatment. This targeted action could lead to fewer side effects and improved outcomes compared to traditional therapies.
What evidence suggests that DCC-2812 might be an effective treatment for advanced genitourinary cancers?
Research has shown that DCC-2812 activates a protein called GCN2, which can slow the growth of cancer cells. This method blocks cancer cells from obtaining certain essential nutrients. Early results suggest effectiveness in treating advanced kidney, bladder, and prostate cancers. Although studies remain in the early stages, DCC-2812's targeted approach to cancer cells shows promise in stopping or slowing their growth. More research is needed to confirm these findings, but the initial data offers hope for those facing these challenging cancers.14567
Who Is on the Research Team?
Clinical Team
Principal Investigator
Deciphera Pharmaceuticals, LLC
Are You a Good Fit for This Trial?
This trial is for adults who can take pills and have advanced or metastatic kidney, bladder, or castration-resistant prostate cancer. They must not be planning to conceive, with women of childbearing age needing a negative pregnancy test. Participants also need their organs to function well and have balanced electrolytes.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive DCC-2812 in a dose escalation manner to evaluate safety and preliminary activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- DCC-2812
Find a Clinic Near You
Who Is Running the Clinical Trial?
Deciphera Pharmaceuticals, LLC
Lead Sponsor